Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

SCRI Development Innovations

Status and phase

Completed

Phase 2

Conditions

Non-Hodgkins Lymphoma

Treatments

Drug: 90Y Zevalin

Drug: Etoposide

Drug: Ifosfamide

Drug: Rituximab

Drug: Carboplatin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193505

SCRI LYM 27

106-P092

Details and patient eligibility

About

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.

Full description

Upon determination of eligibility, patients will receive:

Ifosfamide + Carboplatin + Etoposide + Rituximab

Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma
Persistent lymphoma after one or two previous chemotherapy regimens
Patients should not be considered candidates for high-dose chemotherapy
Ability to perform activities of daily living with assistance
Measurable or evaluable disease
Age > 18 years
Adequate bone marrow, liver and kidney function

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Patients with impaired bone marrow reserve
Female patients who are pregnant or lactating
Serious active infection at the time of treatment
Any other serious underlying condition
Brain or meningeal) with lymphoma
HIV or AIDS-related lymphoma
Received external beam radiation therapy to > 25% of active bone marrow.
History of other cancers, either active or treated

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.